PL2129693T3 - Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae - Google Patents

Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae

Info

Publication number
PL2129693T3
PL2129693T3 PL08732592T PL08732592T PL2129693T3 PL 2129693 T3 PL2129693 T3 PL 2129693T3 PL 08732592 T PL08732592 T PL 08732592T PL 08732592 T PL08732592 T PL 08732592T PL 2129693 T3 PL2129693 T3 PL 2129693T3
Authority
PL
Poland
Prior art keywords
production
purification process
streptococcus pneumoniae
pneumoniae polysaccharides
shortened purification
Prior art date
Application number
PL08732592T
Other languages
English (en)
Inventor
Yonghui Yuan
Mark Ruppen
Wei-Qiang Sun
Ling Chu
John Simpson
James Patch
Charbonneau Pamela Fink
Justin K. Moran
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2129693(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL2129693T3 publication Critical patent/PL2129693T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • C07H1/08Separation; Purification from natural products
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Mycology (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL08732592T 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae PL2129693T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89661607P 2007-03-23 2007-03-23
EP08732592.4A EP2129693B1 (en) 2007-03-23 2008-03-20 Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides

Publications (1)

Publication Number Publication Date
PL2129693T3 true PL2129693T3 (pl) 2017-07-31

Family

ID=39712482

Family Applications (3)

Application Number Title Priority Date Filing Date
PL18177128.8T PL3406635T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
PL11194173T PL2436700T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
PL08732592T PL2129693T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL18177128.8T PL3406635T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
PL11194173T PL2436700T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae

Country Status (30)

Country Link
US (3) US8652480B2 (pl)
EP (3) EP3406635B1 (pl)
JP (5) JP5688902B2 (pl)
KR (2) KR20150021127A (pl)
CN (1) CN101663327B (pl)
AU (1) AU2008231041B2 (pl)
BR (1) BRPI0809212B8 (pl)
CA (1) CA2681570C (pl)
CL (2) CL2008000831A1 (pl)
CO (1) CO6251324A2 (pl)
CR (1) CR11041A (pl)
DK (3) DK2436700T5 (pl)
EC (1) ECSP099652A (pl)
ES (3) ES2614249T3 (pl)
GT (1) GT200900249A (pl)
HK (1) HK1141815A1 (pl)
HN (1) HN2009001965A (pl)
HU (3) HUE031567T2 (pl)
IL (1) IL201106A (pl)
MX (1) MX2009010221A (pl)
MY (1) MY150927A (pl)
NI (1) NI200900172A (pl)
NZ (1) NZ580134A (pl)
PL (3) PL3406635T3 (pl)
PT (3) PT2129693T (pl)
RU (1) RU2516340C2 (pl)
SI (3) SI2129693T1 (pl)
UA (1) UA99278C2 (pl)
WO (1) WO2008118752A2 (pl)
ZA (1) ZA200906625B (pl)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2129693T (pt) * 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
SI2385981T1 (sl) * 2008-12-18 2019-11-29 Wyeth Llc Postopek za nadzorovanje molekulske mase polisaharida streptococcus pneumoniae z uporabo ogljika
BRPI0922981A8 (pt) * 2008-12-18 2019-11-26 Wyeth Llc método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
MX340830B (es) 2009-04-30 2016-07-26 Coley Pharm Group Inc Vacuna neumococica y usos de la misma.
CA2766418C (en) 2009-06-22 2016-03-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
MY169837A (en) 2009-06-22 2019-05-16 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
US9878029B2 (en) * 2011-03-22 2018-01-30 Serum Institute Of India Private Limited Process for preparation of polysaccharides
CN102660601B (zh) * 2012-04-17 2015-10-28 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660603B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 一种快速纯化细菌荚膜多糖的方法
US9650411B2 (en) * 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
CN104781413B (zh) * 2012-09-07 2018-01-23 Sk化学公司 用于具有肺炎球菌血清型的荚膜多糖的生产方法
US9855324B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
SG11201508999UA (en) 2013-07-12 2015-11-27 Emd Millipore Corp A method of determining virus removal from a sample containing a target protein using activated carbon
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
NZ755769A (en) 2014-01-21 2023-06-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102049826B1 (ko) 2014-01-21 2019-12-03 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
AU2015208822B2 (en) 2014-01-21 2020-06-18 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
KR102045663B1 (ko) 2015-05-04 2019-11-15 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
CN108138216A (zh) * 2015-06-18 2018-06-08 般财团法人阪大微生物病研究会 肺炎球菌补体依赖性杀菌能力测量方法
TWI756893B (zh) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CN105131139B (zh) * 2015-07-31 2018-02-13 兰州生物制品研究所有限责任公司 一种肺炎链球菌荚膜多糖的纯化方法
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
WO2018027123A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
EP3562503A2 (en) 2016-12-30 2019-11-06 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
MX2019009867A (es) 2017-02-24 2019-10-02 Merck Sharp & Dohme Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7132954B2 (ja) 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー 改善された免疫原性及び結合活性を提供する2価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
MX2020000224A (es) * 2017-07-05 2020-08-17 Inventprise Llc Purificacion de polisacárido para la produccion de vacuna utilizando enzimas líticas, filtración de flujo tangencial y cromatografía multimodal.
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
BR112020004502A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
CA3074708A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN116898959A (zh) 2017-09-07 2023-10-20 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN107936128B (zh) * 2017-11-22 2020-07-03 成都欧林生物科技股份有限公司 一种简便有效的细菌疫苗纯化方法
WO2019139692A2 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR20210002641A (ko) 2018-04-30 2021-01-08 머크 샤프 앤드 돔 코포레이션 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
CN112543649A (zh) 2018-07-04 2021-03-23 Vaxcyte公司 免疫原性缀合物的改进
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
US12018134B2 (en) * 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
MX2021007496A (es) 2018-12-19 2021-08-05 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso.
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
US20210070890A1 (en) * 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
US20230383324A1 (en) 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
KR20240128715A (ko) 2022-01-13 2024-08-26 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002004B1 (en) 1977-11-07 1982-03-24 Ciba-Geigy Ag Process for the manufacture of fluorinated cationic compounds and their use as surfactants
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
JPS6170994A (ja) * 1984-09-14 1986-04-11 Daikin Ind Ltd 環状(1→2)−β−D−グルカンの製法
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
RU2087156C1 (ru) * 1995-06-22 1997-08-20 Леонид Николаевич Падюков Вакцина против пневмококковой инфекции
EP3118225A1 (en) * 1997-12-23 2017-01-18 Pfizer Ireland Pharmaceuticals Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0108079D0 (en) * 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2604362C (en) * 2005-04-08 2013-11-12 Wyeth Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation
EP2425854A1 (en) * 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
PT2129693T (pt) * 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae

Also Published As

Publication number Publication date
US9675681B2 (en) 2017-06-13
CA2681570A1 (en) 2008-10-02
AU2008231041A8 (en) 2009-11-12
EP3406635A1 (en) 2018-11-28
EP2436700B8 (en) 2018-08-01
ECSP099652A (es) 2009-10-30
RU2516340C2 (ru) 2014-05-20
SI2436700T1 (sl) 2018-09-28
CN101663327B (zh) 2014-05-07
JP2010521972A (ja) 2010-07-01
PT2436700T (pt) 2018-07-17
SI3406635T1 (sl) 2022-08-31
PL2436700T3 (pl) 2018-12-31
ES2614249T3 (es) 2017-05-30
JP2017141263A (ja) 2017-08-17
GT200900249A (es) 2010-07-28
PT2129693T (pt) 2017-02-14
JP2020169160A (ja) 2020-10-15
MX2009010221A (es) 2009-10-19
UA99278C2 (ru) 2012-08-10
US8999697B2 (en) 2015-04-07
KR20150021127A (ko) 2015-02-27
US20150165017A1 (en) 2015-06-18
SI2129693T1 (sl) 2017-01-31
CL2017002029A1 (es) 2018-05-18
JP6825950B2 (ja) 2021-02-03
EP3406635B1 (en) 2022-05-11
IL201106A (en) 2014-04-30
WO2008118752A2 (en) 2008-10-02
ZA200906625B (en) 2010-07-28
US20080286838A1 (en) 2008-11-20
NI200900172A (es) 2010-09-07
KR101500771B1 (ko) 2015-03-18
AU2008231041B2 (en) 2013-03-07
HUE031567T2 (hu) 2017-07-28
CL2008000831A1 (es) 2008-07-04
JP6872649B2 (ja) 2021-05-19
EP2436700A1 (en) 2012-04-04
JP2019048844A (ja) 2019-03-28
DK2436700T5 (en) 2018-09-03
US20140363463A1 (en) 2014-12-11
AU2008231041A1 (en) 2008-10-02
CA2681570C (en) 2016-05-03
EP2436700B1 (en) 2018-06-20
DK2436700T3 (en) 2018-08-13
BRPI0809212A2 (pt) 2014-09-02
NZ580134A (en) 2011-10-28
IL201106A0 (en) 2010-05-17
US8652480B2 (en) 2014-02-18
DK2129693T3 (en) 2017-02-13
DK3406635T3 (da) 2022-05-30
HUE039169T2 (hu) 2018-12-28
KR20100015765A (ko) 2010-02-12
BRPI0809212B1 (pt) 2019-06-18
ES2677353T8 (es) 2018-09-25
PL3406635T3 (pl) 2022-08-22
HN2009001965A (es) 2011-10-06
CN101663327A (zh) 2010-03-03
MY150927A (en) 2014-03-14
PT3406635T (pt) 2022-07-08
RU2009135485A (ru) 2011-04-27
WO2008118752A3 (en) 2008-11-20
ES2677353T3 (es) 2018-08-01
BRPI0809212B8 (pt) 2021-05-25
CO6251324A2 (es) 2011-02-21
HK1141815A1 (en) 2010-11-19
CR11041A (es) 2009-12-30
JP2015143225A (ja) 2015-08-06
HUE059085T2 (hu) 2022-10-28
EP2129693A2 (en) 2009-12-09
ES2922132T3 (es) 2022-09-08
JP5688902B2 (ja) 2015-03-25
EP2129693B1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
ZA200906625B (en) Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides
EP1999134A4 (en) PROCESS FOR PREPARING ANYHYDRUGAL ALCOHOLS
EG25753A (en) Process for the production of alcohols
EP2170919A4 (en) IMPROVED PROCESS FOR THE PRODUCTION OF NUCLEOTIDE SUGARS
EP2189435A4 (en) PROCESS FOR PREPARING A PROPYLENE
IL220430A0 (en) Process for the production of benzopyran-2-ol derivatives
GB0920383D0 (en) Process for the production of sucrose-6-ester
HK1160097A1 (en) Process for the production of ammonia
IL202153A0 (en) Process for the production of pyrazoles
GB0807808D0 (en) Process for the production of oligosaccharides
IL227837A0 (en) A process for purifying theobromine
IL185722A0 (en) Process for the production of methylcobalamin
EP1975146A4 (en) PROCESS FOR PRODUCING 1,6-HEXANEDIOL
ZA201000237B (en) Process for the production of tertiary alcohols
EP2221294A4 (en) PROCESS FOR PREPARING N-CARBAMOYL-TERT.-LEUCIN
PL2194796T3 (pl) Sposób wytwarzania czekolady
EP2108036A4 (en) PROCESS FOR PRODUCING ALCANOLAMINE
EP2221290A4 (en) PROCESS FOR THE PREPARATION OF ALKOXYINDANONE DERIVATIVES
GB0718398D0 (en) Process for the production of alcohols
EP2077259A4 (en) PROCESS FOR THE PRODUCTION OF 2,6-DIMETHYL-1-NAPHTHALDEHYDE
HU0700244D0 (en) Process for the production of alcohol
SI2029567T1 (sl) Postopek za proizvodnjo derivator benzopiran-2-ola
PL381675A1 (pl) Sposób wytwarzania wyrobów porcelanowych
ZA201002012B (en) Catalyst production process